Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) are treated with vasodilators, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylyl cyclase activators, and prostacyclin. Despite recent advances in pharmacotherapy for individuals w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Transl Med
Asıl Yazarlar: Cavasin, Maria A, Demos-Davies, Kimberly M, Schuetze, Katherine B, Blakeslee, Weston W, Stratton, Matthew S, Tuder, Rubin M, McKinsey, Timothy A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2014
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4255666/
https://ncbi.nlm.nih.gov/pubmed/25425003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-014-0314-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller